GLP-1 medications have moved from diabetes treatment to a cultural phenomenon in record time. But beyond the headlines and celebrity endorsements lies a far more complex story.

In Episode 42, Dr. Randy Vogenberg breaks down what GLP-1s actually are, how they function in the body, and why they are reshaping conversations around obesity, metabolic syndrome, cardiovascular risk, and employer health plan budgets. From Ozempic and Wegovy to emerging alternatives, this episode explores the clinical promise, the side effects, and the financial shockwaves hitting plan sponsors across the country.

For pharmaceutical leaders, HR executives, consultants, and policy stakeholders, this conversation goes beyond weight loss. It addresses what happens when innovation outpaces coverage strategy and how benefit decision makers are responding to one of the most disruptive drug classes in recent history.

Key Topics

• What GLP-1 medications are and how they work
• The science behind metabolic syndrome and weight regulation
• GLP-1s vs. SGLT2 inhibitors
• From diabetes treatment to weight loss demand
• GLP-1s as an alternative to bariatric surgery
• Cardiovascular and metabolic benefits
• Side effects and risk considerations
• Employer and government plan coverage challenges
• Budget impact and utilization explosion
• Long-term implications for benefit design and market access
  
  

Episode Chapters with Timestamps
00:00 – Introduction to Healthcare 101: GLP-1s
00:32 – What are GLP-1 medications?
01:01 – How GLP-1s affect appetite, digestion, and blood sugar
02:48 – Understanding metabolic syndrome
04:20 – Lifestyle factors vs. pharmaceutical intervention
05:30 – GLP-1s vs. SGLT2 inhibitors
06:45 – From bariatric surgery to pharmaceutical alternative
07:56 – Plan sponsor perspective and coverage disruption
09:13 – Who qualifies and why coverage changed
09:27 – Side effects and real world risks
10:52 – Cardiovascular approvals and expanded indications
11:59 – Type 1 vs. Type 2 diabetes management
13:46 – Final thoughts on the future of GLP-1s

Michael's LinkedIn

Randy's LinkedIn

Sponsored by:
Peek: A game-changing prescription shopping solution that allows its members to view all their prescription cost options across cash discount programs and their insurance in one easy-to-use platform. Peek is currently being offered to organizations to help both employees and plan sponsors save money on their prescription spend. https://peekmeds.com/.

Institute for Integrated Health (IIH): Health care benefits, insurance coverage regulations, and doing business in the healthcare industry can be complicated. At IIH, Dr. Randy Vogenberg and his team understand these unique challenges and provides strategic guidance customized to every client. To help overcome your unique challenges, IIH delivers education, planning and advisory on market trends, and U.S. health care market intelligence. The firm’s decades of proven success are due to strategic collaboration with associates from the business, clinical, and scientific communities. https://iih-online.com/.